Woodline Partners LP Raises Position in Immunome, Inc. (NASDAQ:IMNM)

Woodline Partners LP lifted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 6.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 980,925 shares of the company’s stock after acquiring an additional 56,533 shares during the period. Woodline Partners LP’s holdings in Immunome were worth $10,417,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in Immunome by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company’s stock worth $4,856,000 after buying an additional 14,775 shares during the period. Magnus Financial Group LLC grew its holdings in Immunome by 107.8% in the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock valued at $569,000 after buying an additional 27,777 shares during the period. Scharf Investments LLC acquired a new position in shares of Immunome during the 4th quarter valued at about $471,000. Three Bridge Wealth Advisors LLC purchased a new position in shares of Immunome during the 4th quarter worth about $293,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Immunome by 2,540.4% during the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock worth $6,888,000 after acquiring an additional 624,045 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

NASDAQ IMNM opened at $8.46 on Friday. The firm has a market capitalization of $736.12 million, a price-to-earnings ratio of -1.04 and a beta of 2.00. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.81. The company’s 50 day moving average price is $7.59 and its 200 day moving average price is $9.72.

Immunome (NASDAQ:IMNM) last issued its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.46 million. Sell-side analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Lake Street Capital initiated coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 target price for the company. Guggenheim decreased their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Lifesci Capital started coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $21.00 target price (down from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Finally, Stephens reissued an “overweight” rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $23.33.

Insider Buying and Selling at Immunome

In related news, Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the acquisition, the director now directly owns 23,615 shares in the company, valued at $193,879.15. The trade was a 42.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay B. Siegall acquired 137,100 shares of the company’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the purchase, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 156,400 shares of company stock valued at $1,160,495 over the last three months. 8.60% of the stock is owned by company insiders.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.